Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 12/2016

01.12.2016 | Vasculitis (L Espinoza, Section Editor)

Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV)

verfasst von: Luis E. Vega, Luis R. Espinoza

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

It is important to recognize factors that might predict poor outcome and prognosis in patients with AAV. The predictors reported in the literature encompass genetic, histopathological, and clinical ones. Genetic studies (genetic predictors) have found genes that are associated with prediction of poor response to treatment, deterioration of renal function, and risk of mortality. Histopathological studies (histopathological predictors) have shown that sclerotic renal lesions are associated with increased risk of progression to end-stage renal disease and death. Lastly, scores (clinical predictors) obtained with tool as FFS, Maldini risk score, VDI, and emerging new biomarkers could potentially be helpful in assessment of prognosis in the future.
Literatur
1.
Kallenberg CG. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10:489–93.CrossRef
2.
• Lyons P, Rayner T, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23. This genome wide association study in AAV patients shows that there are significant genetic contribution to pathogenesis of disease and distinct genetic associations with GPA and MPA.CrossRefPubMedPubMedCentral
3.
Ugarte-Gil MF, Espinoza LR. Genetic of ANCA-associated vasculitides. Curr Rheumatol Rep. 2014;16(7):428.CrossRefPubMed
4.
Chang DY, Luo H, Zhou XJ, et al. Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2012;7:1293–9.CrossRefPubMedPubMedCentral
5.
Persson U, Gullstrand B, Pettersson A, et al. A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fcγ-RIIa genes. Kidney Blood Press Res. 2013;37:641–8.CrossRefPubMed
6.
•• Cao Y, Liu K, Tian Z, et al. PTPN22 R620W polymorphism and ANCA disease risk in white populations: a meta-analysis. J Rheum. 2015;42(2):292–9. A meta-analysis of four studies of the PTPN22 620W allele confers susceptibility to the occurrence and development of ANCA disease in whites, with specific evidence among subsets with GPA, MPA, and PR3 ANCA.CrossRefPubMed
7.
•• Graysson PC, Carmona-Rivera C, Xu L, et al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in ANCA-associated vasculitis. Arthritis and Rheum. 2015;67(7):1922–32. Recently published study using serum from the RAVE study, which investigated biomarkers involved in the pathophysiology of ANCA-associated vasculitis and sought to determine if LDG contribute to gene expression signatures in AAV. Granulocyte-related gene expression was associated with disease activity and relatively poor response to treatment in AAV.CrossRef
8.
Rahmattulla C, Berden A, Bajema I. Kidneys in ANCA-associated vasculitis: what to learn from biopsies? Press Med. 2013;42(4):563–5.CrossRef
9.
Berden A, Ferrario F, Hagen EC, et al. Histopathological classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628.1636.
10.
Chang DY, Wu LH, Liu G, et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant. 2012;27(6):2343–9.CrossRefPubMed
11.
Muso E, Endo T, Itabashi M, et al. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol. 2013;17:659–62.CrossRefPubMed
12.
Ellis CL, Manno R, Racusen LC, et al. New histopathologic classification of anti-neutrophil cytoplasmic antibody associated pauci-immune glomerulonephritis: correlation with renal outcome (Abstract). J Am Soc Nephrol. 2012;23:711A.
13.
Ford S, Polkinghorne K, Longano A, et al. Renal function and sclerotic glomerular injury predict poor prognosis in patients presenting with anti-neutrophil cytoplasmic antibody associated vasculitis (Abstract). J Am Soc Nephrol. 2012;23:711A.
14.
Shah S, Havill J, Rahman MH, Geetha D. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol 2016;35(4):953–960.
15.
Hanaoka H, Ota Y, Takeuchi T, Kuwana M. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis Clin Rheumatol 2016;35(2):495–500.
16.
Tanna A, Guarino L, Tam FWK, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant. 2015;30:1185–92.CrossRefPubMed
17.
Ford GSL, Polkinghorne KR, Longano A, et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis. 2014;63(2):227–35.CrossRefPubMed
18.
Moroni G, Binda V, Leoni A, et al. Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. Clin Exp Rheumatol. 2015;33(Supp 89):S56–63.
19.
Guillevin L, Pagnoux C, Seror R, et al. The Five Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitides Study Group (FVSG) cohort. Medicine. 2011;90:19–27.CrossRefPubMed
20.
Maldini C, Resche-Rigon M, et al. A risk score for predicting short-term incidence of death or relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. Press Med. 2013;42((4) part 2):666.CrossRef
21.
Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012;14:494–500.CrossRefPubMed
22.
Ponte C, Sznajd J, ONeill L, Luqmani RA. Optimization of vasculitis disease assessment in clinical trials, clinical care and long-term databases. Clin Exp Rheumatol. 2014;32(sup.85):S118–25.
23.
• Kronbichler A, Kerschbaum J, Grundingler G, et al. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant 2015. A systematic literature review was performed, which identified 161 marker molecules. They identified promising biomarkers and proposed a biomarker panel comprising CRP and urinary MCP-1 in patients with AAV and renal involvement.
24.
Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1351–9.CrossRef
25.
Dejaco C, Oppl B, Monach P, et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One. 2015;10(3):1–8.CrossRef
26.
Brix S, Stege G, Disteldorf E, et al. CC chemokine ligand 18 in ANCA-associated crescentic glomerulonephritis. J Am Soc Nephrol. 2015;6(9):2105–17.CrossRef
27.
de Souza A, Abdulahad WH, Sosicka P, et al. Are urinary levels of high mobility group box 1 marker of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin and Exp Immunol. 2014;178(2):270–8.CrossRef
28.
Zhang Y, Shi W, Tang S, et al. The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2013;15:R161.CrossRefPubMedPubMedCentral
29.
Willeke P, Kumpers P, Schluter B, et al. Platelet counts as a biomarker in ANCA-associated vasculitis. Scand J Rheumatol. 2015;44:302–8.CrossRefPubMed
30.
Unizony S, Lim N, Phippard DJ, et al. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015;67:535–44.CrossRefPubMedPubMedCentral
31.
Md Yusof MY, Vital EM, Das S, et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis. 2015;74:1734–8.CrossRefPubMed
32.
Molad Y, Tovar A, Ofer-Shiber S. Association of low serum complement 3 with reduced patient and renal survival in anti-myeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract. 2014;126:67–74.CrossRefPubMed
33.
Skoglund C, Carlsen AL, Weiner M, et al. Circulating microRNA expression pattern separates patients with anti-neutrophil cytoplasmic antibody associated vasculitis from healthy controls. Clin Exp Rheumatol. 2015;33:S-64–71.
34.
Shi YY, Li ZY, Zhao MH, Chen M. The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under corticosteroid and cyclophosphamide regimen: a retrospective cohort. Medicine. 2015;94(18):e843–10.1097.CrossRefPubMedPubMedCentral
35.
Tarzi RM, Liu J, Schneiter S, et al. CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens. Clin Exp Immunol. 2015;181(1):65–75.CrossRefPubMedPubMedCentral
36.
Cao Y, Tian Z, Li W, et al. Predictors of treatment resistance and relapses in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol. 2014;41:916–22.CrossRefPubMed
37.
Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2013;65:2441–9.CrossRef
38.
Hassan TM, Hassan AS, Igoe A, et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow-up in ANCA-associated vasculitis. BMC Immunol. 2014;15:20.CrossRefPubMedPubMedCentral
39.
Grau RG. Drug-induced vasculitis. New insights and a changing lineup of suspects. Curr Rheumatol Rep 2015
40.
Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25:990–7.CrossRefPubMedPubMedCentral
41.
Wang H, Sha L-L, Ma T-T, Zhang L-X, Chan M, Zhao M-H. Circulating levels of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2016;11(2):e0148197.CrossRefPubMedPubMedCentral
Metadaten
Titel
Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV)
verfasst von
Luis E. Vega
Luis R. Espinoza
Publikationsdatum
01.12.2016
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 12/2016
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0619-3

Weitere Artikel der Ausgabe 12/2016

Current Rheumatology Reports 12/2016 Zur Ausgabe

Complementary and Alternative Medicine (S Kolasinski, Section Editor)

Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases

Spondyloarthritis (M Khan, Section Editor)

Imaging in Juvenile Spondyloarthritis

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Monogenic Lupus

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years

Spondyloarthritis (M Khan, Section Editor)

Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis

Antiphospholipid Syndrome (S Zuily, Section Editor)

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise